Citation: Marjani A, Gharanjik AM, Saeidi M. Genetic Polymorphism of CYP2C9 among Sistani Ethnic Group in Gorgan. Ann Med Health Sci Res. 2017; 7:20-24.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Abstract

Background: Cytochrome P450 2C9 (CYP2C9) is involved in metabolism of many important drugs and its genotype variations is thought to affect drug efficacy and the treatment process. Aim: The aim of this study was to assess the distribution of CYP2C9 allele and genotypic variants in Sistani ethnic group, living in Gorgan, South East of Caspian Sea and North East of Iran. Subjects and Methods: This study included 140 Sistani, referred to the health center of Gorgan. CYP2C9 genotyping was carried out by Polymerase Chain Reaction -Restriction Fragment Length Polymorphism technique. Results: The allele frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 was 76.1%, 16.1% and 7.8%, respectively. The frequency of CYP2C9*1/*1,CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes was 53.9%, 22.1%, 11.4%, 2.9%, 4.3% and nil, respectively. Conclusions: Our findings demonstrate that different genotypes of CYP2C9 may influence the pharmacokinetics of some drugs. Determining the pharmacokinetic effects of CYP2C9 genotypes may help physicians choose optimal dosage of some drugs for treatment and prevention of their side effects. Since different ethnic groups from all over the world use medications, it is necessary to investigate the pharmacokinetic effects of CYP2C9 genotypes in different populations.

Keywords

Polymorphism of CYP2C9, Sistani ethnic group, PCR-RFLP

Introduction

Cytochrome P450 2C (CYP 2C) subfamily of enzymes metabolizes approximately 20–30% of most pharmaceutical drugs and CYP2C9 is known as its main isoform [1,2]. This enzyme is encoded by a gene located on chromosome 10q24 which shows genetic polymorphism [3]. Variations during genetic polymorphism of this enzyme may change catalytic activity of the enzyme in drug response [3,4]. The CYP2C9 allele frequencies vary among different populations and many studies on CYP2C9 polymorphism in different populations have shown a significant difference in the frequency of alleles and genotypes [5]. This may be the cause of possible ethnic differences in drug response. Variations in genotype of enzyme have shown that the effect of some genotype is the most acute with S-warfarin metabolism when compared to the wild type genotype. Clinical studies have also indicated that subjects with the mutated genotypes need 10- 20% and/or 20-50% lower doses of S-warfarin, when compared to wild type subjects [5]. CYP2C9 is involved in the metabolism of important drugs such as (S)-warfarin, losartan, rosuvastatine, tolbutamide, glipizide, glibenclamide, the diuretic torsemide, phenytoin, flurbiprofen, ibuprofen and diclofenac [6,7]. The mutated alleles of CYP2C9 are CYP2C9*2 and CYP2C9*3, CYP2C9*6, CYP2C9*15, and CYP2C9*25, but CYP2C9*2 and CYP2C9*3 are the most prevalent variants [8,9]. These alleles are also the most common variants in white populations (CYP2C9*2=0.08–0.14% and CYP2C9*3=0.04–0.16%) while, some studies indicated a significantly lower frequency of these alleles among Asian and African populations [10,11]. Some studies have shown that the CYP2C9*2 allele is considered in European, Middle Eastern and Central and South Asian populations. This allele was absent or considered at very low frequencies in Africa, East Asia, Oceania and the Americas. The CYP2C9*3 allele shows the highest frequency in the European and Central/South Asian populations [12]. Some other studies have revealed that the frequency of the CYP2C9*3 allele among Japanese and Taiwanese populations are 2.1% and 1.7%, respectively. Meanwhile, the CYP2C9*2 allele was not detected among the Han Chinese, Japanese and Taiwanese populations [13]. As mentioned earlier, these alleles may change the catalytic activity of CYP2C9 [6] and on the other hand, many studies have shown the variations among different ethnic groups. We have previously studied the genetic polymorphism of CYP2C9 gene among different ethnic groups in Golestan province [14,15]. This study aimed to assess the distribution of CYP2C9 allele and its genotypic variants in Sistani ethnic group in the city of Gorgan, South East of Caspian Sea, and North East of Iran.

Subjects and Methods

This study involved 140 healthy Sistani (people who speak Sistani as native language) who were referred to a health center in Gorgan (South East of Caspian Sea, North East of Iran). The sample size determined under supervision of statistical expert. This study was approved by the Ethical Committee of Research Deputy of Golestan University of Medical Sciences. Written consent was obtained from all the study subjects. The distribution of CYP2C9 allele and its genotypic variants in Sistani ethnic group were determined and compared with other populations. First, 5 ml of blood was obtained from all the subjects into EDTA tubes. Peripheral white blood cells were used for DNA extraction by salting-out method [16]. Two times distillated water was used to dissolve the extracted DNA. Collected samples were stored at -20oC. CYP2C9*1, CYP2C9*2, and CYP2C9*3 alleles genotyping were performed by Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) technique using Genetix CG palm-thermocycler (India) [17]. The PCR was done in a 25μl reaction mixture including: PCR buffer (10 mM Tris–HCl, pH 9, 2 mM MgCl₂ (Fermentas), 50mM KCl (Fermentas), 0.2 mM deoxyribonucleotide triphosphate (dNTP) mix, 1 U/μl Taq polymerase (Fermentas), 0.4 μM of each primer (Bioneer), 100 ng DNA (Genomic) and two times distillated water. Digestion of PCR products (10μl) was performed using restriction enzymes (Fermentas), Ava II for CYP2C9*2 and Kpn I for CYP2C9*3 at 37 oC for 16 hours. Primer amplification was done using the method explained previously by Aithal et al. [18].

The PCR amplification conditions for CYP2C9*2 included: Initial denaturation(95°C, 10 minutes), number of cycle (45 cycles at 95°C for 5 seconds), denaturation (67°C, 10 seconds), annealing (72°C, 15 seconds), extension and final extension (72°C, 5 minutes). The parameters for CYP2C9*3 were 94°C, 5 minutes.; 33; 94°C, 45 seconds.; 66°C, 45 seconds.; 72°C, 60 seconds and 72°C, 5 minutes, respectively.

Figures 1 and 2 show the PCR products before and after digestion with the restriction enzymes for CYP2C9*2 and CYP2C9*3 genotypes. Agarose gel (3%) was used to perform electrophoresis of (Apelex, France) CYP2C9*2 and CYP2C9*3 DNA fragments. The gel was stained with ethidium bromide, and a Polaroid Gel Camera with black and white film was used to detect the bands. Detection of CYP2C9*2 and CYP2C9*3 mutations were done using sense and antisense primers as described below:

Figure 1: PCR-RFLP analysis of CYP2C9*2 genotypes.

Figure 2: PCR-RFLP analysis of CYP2C9*3 genotypes.

For CYP2C9*2 detection:

Sense primer: 3’ CAC TGG CTG AAA GAGS CTA ACA GAG 5’

Antisense primer: 3’ GTG ATA TGG AGT AGG GTC ACC CAC5’

For CYP2C9*3 detection:

Sense primer: 5’-AATTACAACCAGAGCTTGGC-3’

Antisense primer: 5’-TATCACTTTCCATAAAAGCAAG-3’

Chi-squared test was carried out to determine and compare the allele and genotype frequencies of CYP2C9. The frequency of alleles variant was determined using 95% confidence intervals (95% CI). Fisher exact test was used to compare the variations of allele and genotype frequencies between Sistani ethnic group and other populations. The analysis of data was done using SPSS version 16.0 and p-value of less than 0.05 was considered as statistically significant.

Results

The distribution of the CYP2C9 alleles and genotype frequencies in the Sistani ethnic group are shown in Table 1. The allele frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 was 76.10% (95% CI: 71-81.20), 16.10% (95% CI: 11.70-20.50) and 7.80% (95% CI: 4.60-11), respectively. Tables 2 and 3 demonstrate the differences in allele and genotype frequencies between the Sistani ethnic group and other populations using the Fisher exact test. Table 2 shows a significant difference in CYP2C9*1 allele of the Sistani ethnic group with Iranian Turkmen (88%), [18] Southern Iranians (64.88%), [19] Mongolians in China (97%), [20,21] Japenese (97.30%), [22-24] Russians (82.7%), [25,26] Macedonians (83.10%), [27,28] and Mestizo Mexicans (91%). [29] There was also a significant difference in CYP2C9*2 allele of this ethnic group with Iranian Turkman (8%), [18] Southern Iranians (25.3%), [19] Mongolians in China (0%), [21] Russians (10.5%), [25] Macedonians (10.1%), [27] Southeastern Europeans (11.3%) [28] and Mestizo Mexicans (5.1%). [29] The results also showed that 50.3% of the Sistani subjects had the CYP2C9*1/*1 genotype. In the meanwhile, 22.1%, 11.4%, 2.9%, 4.3% and none of the subjects had CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, respectively. Table 3 shows that the prevalence of CYP2C9*1/*1 among the Sistani ethnic group (59.30%) was higher than the Southern Iranians (41.21%), [19] but lower in comparison with Iranian Turkmen (76.36%), [18] Mongolians in China (93%), [21] Japanese (94.7%), [22] Macedonians (79.8%) [27] and Mestizo Mexicans (83%). [29] The most frequently observed mutant allele was CYP2C9*1/*2 allele (22.1%). Our results showed that CYP2C9*1/*3 genotype (11.4%) was higher in the Sistani ethnic group compared to the Japanese (5.3%), [22] Macedonians (0%) [27] and Mestizo Mexicans (6.8%) [29] [Table 3]. The prevalence of CYP2C9*2/*2 genotype (2.9%) was higher than Mongolians in China (0%), [21] Japanese (0%), [22] Southern Europeans (0.6%) and Mestizo Mexicans (0.4%). [29] The prevalence of CYP2C9*2/*3 genotype (4.3%) was higher than Mongolians in China (0%), [21] Japanese (0%), [22] Hungarians (1.5%) [26] and Mestizo Mexicans (0.7%) [29].

Table 1: CYP2C9 genotype and allele frequencies of the Sistani ethnic group

Table 2: Distribution of CYP2C9 alleles among the Sistani ethnic group and its comparison with other populations

Table 3: Distribution of CYP2C9 genotypes among the Sistani ethnic group and its comparison with other populations

Discussion

Genotype identification is the most important challenges in the future. There are different ethnic groups in various areas of Iran. Many drugs are metabolized by the cytochrome P450 2C9 enzyme [7,19]. Decreased metabolism of some drugs may be associated with the presence of CYP2C9*2 and CYP2C9*3 alleles [20–24]. Alteration in CYP 2C9 genetic polymorphism may affect drug response and enzyme activity. The results of this study showed CYP2C9*1 as the most prevalent allele in the Sistani ethnic group (76.1%). Table 3 shows significant differences in the frequencies of CYP2C9*2 and CYP2C9*3 allelic variants between different populations. The prevalence of CYP2C9*2 in Southern Iranian [25] was higher compared with the Sistanis, but the prevalence of CYP2C9*2 in the Sistani ethnic group was higher than other ethnic groups [21-22,25,27-29]. The prevalence of CYP2C9*3 polymorphism in Sistanis (7.8%) was higher than other populations [21-22,29]. Studies have shown that the CYP2C9*3 and CYP2C9*2 alleles are responsible for reduction of metabolic activity when compared with CYP2C9*1 [1]. A study has indicated that the CYP2C9*2 and CYP2C9*3 alleles, have been associated with an elevated risk of warfarin over bleeding events and anticoagulation [30]. Metabolism of some drugs such as glibenclamide and glimepiride may be affected by different genetic polymorphisms of CYP2C9 [31-32]. Studies have also shown that metabolism of glibenclamide in heterozygous and homozygotes subjects with the CYP2C9*3 allele, was decreased 2.8 and 0.5 folding in comparison to the wild-type genotypes, respectively [1,32]. Some other studies on glipizide have revealed that homozygotes subjects with the CYP2C9*3 allele may be involved in complications of hypoglycemia [33]. The prevalence of CYP2C9*1/*1 in the Sistani ethnic group was higher than Southern Iranian (41.21%) [19]and lower than Iranian Turkmen (76.36%), Mongolian in China (93%), Japanese (94.70%), Macedonian (79.80%) and Mestizo Mexican (83%) [15,21-22,27,29]. The prevalence of CYP2C9*1/*2 genotype was lower [19] and higher [21-22,29] in comparison with other ethnic groups. Our results show that CYP2C9*1/*3 genotype was higher [22,27,29] than other populations. The prevalence of CYP2C9*2/*2 [21-22,28-29] and CYP2C9*2/*3 [21-22,26-27,29] genotypes were higher than different other populations. In this study, the prevalence of CYP2C9*3/*3 genotype showed no significant difference when compared with other populations. Numerous studies have demonstrated that the frequency of CYP2C9*3/*3 genotype is either very low or undetectable [19,23,25,34-39]. Also, variation of CYP2C9*3/*3 genotype may affect drug effectiveness in some ethnic group. Genetic polymorphisms, especially the homozygous with CYP2C9*3 allele, can lead to a significant impairment in metabolic activity of CYP2C9 in different ethnic groups.

Conclusion

In this study, the genotypic variations of the CYP2C9 allele among the Sistani ethnic group was investigated and great differences were observed in comparison to other populations. Our findings demonstrate that different genotypes of CYP2C9 may influence the pharmacokinetics of some drugs. Determining the pharmacokinetic effects of CYP2C9 genotypes may help physicians choose optimal dosage of some drugs for treatment and prevention of their side effects. Since different ethnic groups from all over the world use medications, it is necessary to investigate the pharmacokinetic effects of CYP2C9 genotypes in different populations.

Acknowledgements

The authors would like to thank the deputy of research and technology of Golestan University of Medical Sciences, Iran.

REFERENCES

1. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data. Pharmacogenetics. 2002; 12:251–263.
2. Goldstein JA, De Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994; 4:285–299.
3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001; 52:349–355
4. Garcı´a-Martı´n E, Martı´nez C, Ladero JM, Agu´ndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006; 10:29–40.
5. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005; 7:97-104.
6. Miners J, Birkett D. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998; 45:525–538.
7. Zanger U, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 2008; 392:1093–1108.
8. Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002; 54:518-521.
9. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005; 77:353-364.
10. Van Booven D, Marsh S, McLeod H, Carrillo MW Sangkuhl K, Klein TE. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010; 20:277–281.
11. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012; 27:9–54.
12. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra, EJ. World allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet. 2010; 55:582–589.
13. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006; 80: 169-178.
14. tabari m g, naseri f, agh ataby m, marjani a. genetic polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group. The Open Biochemistry Journal. 2015; 9:37-41.
15. Agh Ataby O, Ghiyas Tabari R, Mansourian AR, Mansour Samai N, Marjani A. Genetic polymorphism of cytochrome P450 2C9 (CYP2C9) in Two Ethnic Groups in Iran. Am. J. Biomed. Sci. 2013; 5:177-187.
16. Chang M, Dahl M., Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995; 5:358–363.
17. Brosen K, De Morais SMF, Meyer UA, Goldstein JA. (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics. 1995; 5:312–317.
18. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353:717–719.
19. Azarpira N, Namazi S, Hendijani F, Banan M, Darai M. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacological Reports. 2010; 62:740-746.
20. Mirghani RA, Chowdhary G, Elghazali G. Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Basic & clinical pharmacology & toxicology. 2011; 109:111-114.    
21. Yang Z, Cui H, Hasi T, Jia S, Gong M, Su X. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res. 2010; 9:1844-1851.
22. Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K. Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population. International journal of medical sciences. 2015; 12:78.
23. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug‐metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundamental & clinical pharmacology. 2007; 21:419-426.
24. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacological Research. 2004; 50:195-200.
25. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. European journal of clinical pharmacology. 2003; 59:303-312.
26. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, et al. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells, Molecules, and Diseases. 2009; 43:239-42.
27. Jakjovski K, Labachevski N, Petlichkovski A, Senev A, Trojacanec J, Atanasovska E, et al. Distribution of CYP2C9 and VKORC1 Gene Polymorphisms in Healthy Macedonian Male Population. Macedonian Journal of Medical Sciences. 2013; 6:339-343.
28. Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S. Analysis of CYP2C9* 2, CYP2C9* 3 and VKORC1‐1639 G> A polymorphisms in a population from South‐Eastern Europe. Journal of Cellular and Molecular Medicine. 2012; 16:2919-2924.
29. Castelán-Martínez OD, Hoyo-Vadillo C, Sandoval-García E, Sandoval-Ramírez L, González-Ibarra M, Solano-Solano G, et al. Allele frequency distribution of CYP2C9* 2 and CYP2C9* 3 polymorphisms in six Mexican populations. Gene. 2013; 523:167-172
30. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM. Association between CYP2C9 genetic variants and anticoagulation-Related outcomes during warfarin therapy. Journal of the American Medical Association. 2002; 287:1690-1698.
31. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002; 71:286–296.
32. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72:326–332.
33. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999; 9:71–80.
34. Yasar U, Eliasson E, Dahl ML. Johansson I, Ingelman- Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 1999; 254:628–631.
35. Herman D, Dolzan V, Breskvar K. Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. Zdrav. Vestn. 2003; 72:347–351.
36. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106: 2329–2333.
37. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 2002; 53:596–603.
38. Isaza C, Henao J, Martínez JH, Arias JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC. Clin. Pharmacol. 2007; 7:6.
39. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin. Exp. Pharmacol. Physiol. 2007; 34:102–105.